



2018 Disclosure of Interest Information

GOLD BOARD OF DIRECTORS

Alvar G. Agusti, MD, *Chair*

Bartolome R. Celli, MD

Rongchang Chen, MD

Gerard Criner, MD

Peter Frith, MD

David Halpin, MD

M. Victorina López Varela, MD

Sundeeep Salvi MD, PhD, FCCP, FRCP

Claus Vogelmeier, MD

GOLD SCIENCE COMMITTEE

Claus Vogelmeier, MD, *Chair*

Alvar G. Agusti, MD

Antonio Anzueto, MD

Peter J. Barnes MD

Jean Bourbeau, MD

Gerard Criner, MD

Peter Frith, MD

David Halpin, MD

MeiLan Han, MD MS

Fernando Martinez, MD

Maria Montes de Oca, MD

Alberto Papi, MD

Ian Pavord MA DM FRCP FERS FMedSci

Nicolas Roche, MD

Don D. Sin, MD

Dave Singh, MD

Rob Stockley, MD

Joergen Vestbo

M.Victorina López Varela, MD

Jadwiga A. Wedzicha, MD

GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (GOLD) DISCLOSURE OF FINANCIAL INTEREST

January 1, 2018 - December 31, 2018

Background

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program is a collaboration between the scientific community and the private sector. The major objectives are: (1) to increase awareness of Chronic Obstructive Lung Disease among health professionals, health authorities, and the general public; (2) improve diagnosis, management, and prevention; and (3) stimulate research. These objectives are being met through preparation of scientific reports on Chronic Obstructive Lung Disease, dissemination and adoption of recommendations in these reports, and promotion of international collaboration on Chronic Obstructive Lung Disease research.

The purpose of this document is to safeguard the interests of all GOLD collaborators by an open disclosure of interests.

GOLD Structure

At present, the GOLD program is conducted through a GOLD Board of Directors that meets annually (usually in January), a Scientific Committee and a Dissemination Committee. Each Committee will have an active role in reviewing and recommending content for GOLD documents and all members will be asked to complete this form.

Annual Declaration of Interests

The following declarations are requested by GOLD. Please complete the company name select in the corresponding box whether you have financial relationships (received grants, personal fees, shares, non-financial support, other). Please include all companies in the bio-medical arena, as well as telehealth/technology, and tobacco entities. This form will be posted on the GOLD website after completion.

Definitions:

1. **Grants:** refers to any grant paid to your organization.
2. **Personal Fees:** refers to honorarium, consultation fees, etc for lectures, advisory committees or consultancy services either intermittent or regular, from which a GOLD member benefits personally. This includes ongoing attendance at advisory board meetings but would not normally include a situation where an individual is paid for a specific item or for attending or speaking at an occasional meeting.
3. **Shares:** refers to any shares in Chronic Obstructive Lung Disease-related commercial organizations, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GOLD member or family members (spouse/children). The company is to be listed, not the number of shares.
4. **Non-Financial Support:** In-kind assistance.

The private sector should not in any way be involved in any aspect of developing documents, including collecting, reviewing or accessing the literature or determining the content. Once documents have been produced Chronic Obstructive Lung Disease-related commercial organizations can be involved in their dissemination and audit, including support for publications.

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Gerard Criner

Member of: GOLD Board of Directors, GOLD Science Committee

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
Amgen, Inc.		X			
AstraZeneca		X			
Boehringer Ingelheim Pharmaceuticals, Inc.	X	X			
Bronchus Medical, Inc.	X	X			
Chiesi Farmaceutici S.p.A.,		X			
GlaxoSmithKline, LLC	X	X			
HGE Health Care Solutions, LLC		X			
Hospicom, Inc.		X			
MedScape, LLC		X			
Mereo Biopharma Group PLC		X			
Novartis Pharma AG		X			
Nuvaira, Inc.	X	X			
Olympus America, Inc.		X			
PneumRx, Inc.	X	X			
Prometic Life Sciences, Inc.	X	X			
Pulmonx Corp.	X	X			
Respironics, Inc.		X			
Saint Barnabas Medical Center		X			
Sanofi US Services, Inc.	X	X			
Uptake Medical Technology, Inc.		X			
Verona		X			
Amgen, Inc.		X			
AstraZeneca		X			

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Peter Anthony Frith

Member of: GOLD Board of Directors, GOLD Science Committee, Assembly

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
Asthma Australia			Yes		Speaker travel support
Boehringer Ingelheim		Yes	Yes		Speaker & advisory board fees & travel support
GlaxoSmithKline		Yes	Yes		Speaker and advisory board fees and travel support
Lung Foundation Australia			Yes		Travel support to Board meetings
CSL-Behring		Yes	Yes		Speaker and advisory board fees and travel support
Menarini		Yes	Yes		Speaker and advisory board fees and travel support
Mundipharma		Yes	Yes		Speaker and advisory board fees and travel support
Novartis		Yes	Yes		Speaker and advisory board fees and travel support
Medicine Today		Yes			Honorarium for writing and editorial work
GOLD			Yes		Travel support for Board meetings
AstraZeneca		Yes	Yes		Speaker and advisory board fees and travel support
Australian Doctor		Yes			Honorarium for writing and editorial work

Salvi

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Kevin Mortimer

Member of: Gold Board of Directors

Are there any relevant financial interests to disclose? Yes

Research grants:

- 2015 **Medical Research Council Doctoral Training Partnership.** Biagini G, Mortimer K (co-lead) and Diggle P. **£1.3m.** Translational and Quantitative Skills Doctoral Training Partnership in Global Health
- 2016 **Medical Research Council.** Mortimer K (PI). **£606,000.** Lung Health in Africa across the life course
- 2017 **National Institute for Health Research.** Squire SB, Mortimer K (co-I) et al. **£7m.** NIHR Global Health Research Unit on Lung Health and Tuberculosis in Africa at LSTM
- 2017 **Medical Research Council.** Biagini G, Mortimer K (co-lead) and Diggle P. **£257,469.** Liverpool School of Tropical Medicine and Lancaster University NPIF Studentships
- 2017 **Medical Research Council Skills Development Fellowship Programme.** Mortimer K (PI). **£580k.** Translational and Quantitative Skills Development Fellowships in Global Health
- 2017 **Medical Research Council NPIF Skills Development Fellowship.** Mortimer K (PI). **£286,000.** Translational and Quantitative NPIF Skills Development Fellowship in Global Health
- 2017 **Medical Research Council.** Allen S (PI), Mortimer K (co-I) et al. **£218,002.** Improving the survival, growth and developmental of low birth weight newborns through better nutrition
- 2018 **Medical Research Council.** Biagini G, Mortimer K (co-lead) and Diggle P. **£188,132.** Liverpool School of Tropical Medicine and Lancaster University NPIF Studentships
- 2018 **National Institute for Health Research.** Grigg J, Mortimer K (co-I) et al. **£2m.** NIHR Global Health Research Unit on improving asthma outcomes in African children at Barts and The London Queen Mary's School of Medicine and Dentistry
- 2018 **Wellcome Trust** Clinical PhD. Awarded to Sepedeh Saleh. Mortimer K (primary supervisor). **£455,000.** A new approach to air pollution in peri-urban Malawi.
- 2018 **The Academy of Medical Sciences.** Lesosky M (PI) and Mortimer K (co-I). **£92.6k.** Newton Advanced Fellowship: Biostatistical Methods for Bayesian Analysis of Multilevel Models of Lung Health in Africa.
- 2018 **Medical Research Council and Kenya National Research Fund Newton-Utafiti.** Mortimer K and Muhwa C (co-PIs). **£715k.** Non-communicable lung disease in Kenya: from burden and early life determinants to participatory inter-disciplinary solutions.
- 2018 **Medical Research Council Skills Development Fellowship Programme.** Mortimer K (PI). **£580k.** Translational and Quantitative Skills Development Fellowships in Global Health

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
International Union against Tuberculosis and lung disease (The Union)		X			KM is Director of Lung Health for The Union

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Fernando Jose Martinez

Member of: GOLD Science Committee

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
AstraZeneca	X	X	X		COPD Advisory Boards, Study Steering Committee including travel
Boehringer Ingelheim		X	X		COPD Advisory Board including travel
ProTERRIX Bio			X		COPD Advisor without financial support
Chiesi		X	X		COPD Advisory Board including travel
GlaxoSmithKline	X	X	X		COPD Advisory Boards, DSMB and Study Steering Committees including travel
Sunovion		X	X		COPD Advisory Board including travel
Teva		X	X		COPD Advisory Board including travel
Verona			X		COPD Advisory without financial support

**GLOBAL INITIATIVE FOR CHRONIC
OBSTRUCTIVE LUNG DISEASE (GOLD)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Dave Singh

Member of: GOLD Science Committee

Are there any relevant financial interests to disclose? (Yes or No in each box)

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
AstraZeneca	Y	Y			
Boehringer Ingelheim	Y	Y			
Chiesi	Y	Y			
Cipla		Y			
Genentech		Y			
GlaxoSmithKline	Y	Y			
Glenmark	Y	Y			
Menarini	Y	Y			
Mundipharma	Y	Y			
Novartis	Y	Y			
Peptinnovate		Y			
Pfizer	Y	Y			
Pulmatrix	Y	Y			
Verona	Y	Y			

